Ποια είναι η τιμή για Aptose Biosciences Inc. (APS)

Η τιμή για Aptose Biosciences Inc. (APS) είναι $1.76

Ποια είναι η κεφαλαιοποίηση αγοράς για Aptose Biosciences Inc. (APS)

Η κεφαλαιοποίηση αγοράς για Aptose Biosciences Inc. (APS) είναι $4.50M

Aptose Biosciences Inc. (APS) Τιμή και Κεφαλαιοποίηση Αγοράς

Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.

Η τιμή για APS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$2,135,872 $4.50M	NVDA	$5.452T	+121,256,489.11%
$1,759,050 $4.50M	AAPL	$4.490T	+99,863,755.36%
$1,630,702 $4.50M	GOOG	$4.162T	+92,577,215.20%
$1,440,277 $4.50M	MSFT	$3.676T	+81,766,510.34%
$1,109,898 $4.50M	AMZN	$2.833T	+63,010,431.88%

Η τιμή για APS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$2,135,872 $4.50M